Ultragenyx Pharmaceutical (RARE) Revenue (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) has 11 years of Revenue data on file, last reported at $136.0 million in Q1 2026.

• On a quarterly basis, Revenue fell 2.16% year-over-year to $136.0 million in Q1 2026; TTM through Mar 2026 was $669.7 million, a 13.48% increase from a year earlier, with the FY2025 full-year figure at $673.0 million, up 20.18% from the prior year.
• Revenue for Q1 2026 stood at $136.0 million, down from $207.3 million in the prior quarter.
• Over the last five years, Revenue for RARE reached as high as $207.3 million in Q4 2025 and fell as low as $79.9 million in Q1 2022.
• Historically, Revenue has averaged $127.4 million across 5 years, with a median of $127.1 million in 2023.
• Across the five-year window, Revenue slipped 19.58% in 2022 and surged 42.27% in 2024, its largest moves.
• Year by year, Revenue stood at $103.3 million in 2022, then increased by 23.02% to $127.1 million in 2023, then grew by 29.5% to $164.6 million in 2024, then advanced by 25.89% to $207.3 million in 2025, then sank by 34.39% to $136.0 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $136.0 million in Q1 2026, $207.3 million in Q4 2025, and $159.9 million in Q3 2025.